Holen Sie sich die Stockscreener-App
1.52
10.14%
0.14
Handel nachbörslich:
1.55
0.03
+1.97%
Schlusskurs vom Vortag:
$1.38
Offen:
$1.41
24-Stunden-Volumen:
2.63M
Relative Volume:
1.14
Marktkapitalisierung:
$178.85M
Einnahmen:
$1.55M
Nettoeinkommen (Verlust:
$-63.06M
KGV:
-1.9098
EPS:
-0.7959
Netto-Cashflow:
$-49.45M
1W Leistung:
+50.50%
1M Leistung:
-3.80%
6M Leistung:
-28.30%
1J Leistung:
+118.48%
1-Tages-Spanne:
$1.38
$1.53
1-Wochen-Bereich:
$1.06
$1.53
52-Wochen-Spanne:
$0.6254
$3.06
Milestone Pharmaceuticals Inc Stock (MIST) Company Profile
Firmenname
Milestone Pharmaceuticals Inc
Sektor
Branche
Telefon
(514) 336-0444
Adresse
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, QC
Compare MIST vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MIST
Milestone Pharmaceuticals Inc
|
1.52 | 162.38M | 1.55M | -63.06M | -49.45M | -0.7959 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Milestone Pharmaceuticals Inc Stock (MIST) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-15 | Hochstufung | TD Cowen | Hold → Buy |
| 2025-09-11 | Eingeleitet | Wells Fargo | Overweight |
| 2025-06-05 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-08-22 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-06-20 | Herabstufung | Jefferies | Buy → Hold |
| 2022-04-22 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-03-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-07-29 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-07-24 | Hochstufung | Jefferies | Hold → Buy |
| 2020-03-25 | Herabstufung | Jefferies | Buy → Hold |
| 2020-03-24 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-03-24 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2019-06-04 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-03 | Eingeleitet | Cowen | Outperform |
| 2019-06-03 | Eingeleitet | Jefferies | Buy |
| 2019-06-03 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Milestone Pharmaceuticals Inc Aktie (MIST) Neueste Nachrichten
Buybacks Report: Does Milestone Pharmaceuticals Inc offer margin of safetyMarket Activity Recap & Scalable Portfolio Growth Methods - baoquankhu1.vn
Three new hires get 123,000 Milestone stock options under Nasdaq rule - Stock Titan
Institution Moves: Is Milestone Pharmaceuticals Inc undervalued by DCF analysis2026 Earnings Impact & Free Community Consensus Stock Picks - baoquankhu1.vn
MIST Stock Price, Quote & Chart | MILESTONE PHARMACEUTICALS IN (NASDAQ:MIST) - ChartMill
Trails Edge Capital Partners, LP Acquires 5,333,333 Shares in Mi - gurufocus.com
Milestone Pharmaceuticals Announces that CARDAMYST (etripamil) Nasal Spray is Available on Express Scripts Commercial National Formularies - Bitget
Milestone Pharmaceuticals (MIST) Secures Formulary Inclusion for Cardamyst - gurufocus.com
Milestone Pharmaceuticals Announces that CARDAMYST™ (etripamil) Nasal Spray is Available on Express Scripts Commercial National Formularies - The Manila Times
Express Scripts adds new PSVT nasal spray to national formularies - Stock Titan
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Milestone Pharmaceuticals gears up for Q4 print; here are the recent forecast changes from Wall Street's most accurate analysts - MSN
Milestone Pharmaceuticals (NASDAQ:MIST) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Published on: 2026-03-28 09:41:33 - baoquankhu1.vn
Published on: 2026-03-28 10:15:13 - baoquankhu1.vn
Milestone Pharmaceuticals Stock: Trails Edge Discloses 4.3% Stake Amid Q4 Earnings Anticipation - AD HOC NEWS
Trails Edge files amended 4.3% stake disclosure in Milestone Pharmaceuticals (MIST) - Stock Titan
Aug Chart Watch: Is Milestone Pharmaceuticals Incs ROIC above industry averageForecast Cut & Daily Stock Trend Watchlist - baoquankhu1.vn
Milestone Pharmaceuticals Faces Increased Risk Amid Mixed Technical and Valuation Signals - Markets Mojo
Milestone Pharmaceuticals (MIST) Projected to Post Earnings on Tuesday - MarketBeat
Milestone Pharmaceuticals Inc. (MIST) GC reports 400,000-share stock option - Stock Titan
Equities Analysts Issue Forecasts for MIST FY2028 Earnings - marketbeat.com
Milestone Pharmaceuticals Faces Financial Challenges amidst Market Shifts - timothysykes.com
Regulatory Disruptions Pose Material Operational Risks for Milestone Pharmaceuticals - The Globe and Mail
MIST PE Ratio & Valuation, Is MIST Overvalued - Intellectia AI
Milestone Pharmaceuticals (NASDAQ:MIST) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
Why Milestone Pharma Stock Is Taking A Dive Today - Sahm
Why Milestone Pharma stock is taking a dive today - MSN
How does Milestone Pharmaceuticals Inc compare to its peersIndex Update & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Milestone Pharmaceuticals Inc (MIST) Q4 2025 Earnings Call Highl - GuruFocus
S P Trends: Does Milestone Pharmaceuticals Inc have consistent dividend growth2026 Top Decliners & Comprehensive Market Scan Reports - baoquankhu1.vn
Buyback Watch: What is the long term forecast for Milestone Pharmaceuticals Inc stock2026 Winners & Losers & Verified Momentum Stock Alerts - baoquankhu1.vn
Milestone Pharmaceuticals Inc (MIST) Q4 2025 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
Milestone Pharma Faces Earnings Hurdles Amidst Market Fluctuations - StocksToTrade
Milestone: Early CARDAMYST Launch Progress and Solid Cash Position Underscore Buy Rating and $8 Target - TipRanks
Missing Data on MIST: Insights and Analysis - timothysykes.com
Milestone Pharmaceuticals Reports 2025 Financial Results and Launch of FDA-Approved CARDAMYST Nasal Spray for PSVT - Minichart
Milestone Pharmaceuticals 2025 Annual Report: CARDAMYST™ (etripamil) Launch, Business Overview, and Key Risks - Minichart
Milestone Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Milestone Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Milestone Pharmaceuticals meets EPS forecast, stock dips - Investing.com
Milestone Advances CARDAMYST Launch After Landmark PSVT Approval and Bolsters Cash Runway - TipRanks
Milestone Pharmaceuticals: Fourth Quarter Earnings Overview - Bitget
Milestone Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Milestone Pharmaceuticals (MIST) Reports Strong Financial and Ma - gurufocus.com
Milestone Pharmaceuticals reports Q4 EPS (16c), consensus (18c) - TipRanks
Milestone Pharmaceuticals: Q4 Earnings Snapshot - Barchart.com
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST™ (etripamil) Nasal Spray for the Treatment of PSVT - The Manila Times
CARDAMYST launch and 2025 results for Milestone Pharmaceuticals (Nasdaq: MIST) - Stock Titan
Milestone Pharmaceuticals Announces FDA Approval of CARDAMYST™, the First New Treatment for PSVT in 30 Years - Quiver Quantitative
Milestone Pharmaceuticals 10‑K: $1.55M Revenue, ($0.75) EPS on $63.1M Net Loss - TradingView
Earnings Scheduled For March 20, 2026BitFuFu (NASDAQ:FUFU), Milestone Pharmaceuticals (NASDAQ:MIST) - benzinga.com
Finanzdaten der Milestone Pharmaceuticals Inc-Aktie (MIST)
Umsatz
Nettogewinn
Free Cashflow
ENV
Milestone Pharmaceuticals Inc-Aktie (MIST) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Bharucha David | Chief Medical Officer |
Jan 26 '26 |
Sale |
1.93 |
12,245 |
23,633 |
113,181 |
| Nelson Jeffrey Edward | Chief Operating Officer |
Dec 15 '25 |
Sale |
2.32 |
58,007 |
134,576 |
41,993 |
| Nelson Jeffrey Edward | Chief Operating Officer |
Jan 26 '26 |
Sale |
1.93 |
12,245 |
23,633 |
49,848 |
| Muller Lorenz | Chief Commercial Officer |
Dec 15 '25 |
Sale |
2.32 |
53,566 |
124,273 |
196,486 |
| Muller Lorenz | Chief Commercial Officer |
Jan 26 '26 |
Sale |
1.93 |
11,180 |
21,577 |
205,406 |
| Hasija Amit | CFO & EVP of Corp. Development |
Dec 15 '25 |
Sale |
2.32 |
58,007 |
134,576 |
91,993 |
| Hasija Amit | CFO & EVP of Corp. Development |
Jan 26 '26 |
Sale |
1.93 |
12,245 |
23,633 |
99,848 |
| Oliveto Joseph | President and CEO |
Dec 15 '25 |
Sale |
2.32 |
133,054 |
308,685 |
450,667 |
| Oliveto Joseph | President and CEO |
Jan 26 '26 |
Sale |
1.93 |
34,523 |
66,629 |
482,744 |
| Oliveto Joseph | President and CEO |
Jan 08 '26 |
Sale |
2.25 |
43,000 |
96,750 |
303,721 |
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):